A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy-Reference-Cited by-同舟云学术

A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy

Published:2008-07-15 Issue:2 Volume:198 Page:234-240
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:J INFECT DIS

Author:

Cameron D. William,da Silva Barbara A.,Arribas Jose R.,Myers Robert A.,Bellos Nicholaos C.,Gilmore Norbert,King Martin S.,Bernstein Barry M.,Brun Scott C.,Hanna George J.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/198/2/234/18054204/198-2-234.pdf

Reference14 articles.

1. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients

2. Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression

3. A Pilot Study of Switch to Lopinavir/Ritonavir (LPV/r) Monotherapy from Nonnucleoside Reverse Transcriptase Inhibitor–Based Therapy

4. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice

5. Ruane P, Luber A, Gaultier C. etal Maintenance therapy using lopinavir/ritonavir (LPV/r) alone with well-controlled HIV-infection [abstract TuPeB4577]. Available at: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=2174887. Accessed 30 May 2008.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THERAPEUTIC STRATEGIES AND USE OF LOPINAVIR/RITONAVIR IN PATIENTS WITH HIGHLY RESISTANT HUMAN IMMUNODEFICIENCY VIRUS;FARMACIA;2024

2. Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus;Medicine;2022-12-09

3. Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy;British Journal of Clinical Pharmacology;2022-01-26

4. Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat;Biomedicines;2021-03-18

5. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial;The Lancet HIV;2020-10